References
- Buchdunger E, Cioffi CL, Law N, et al: Abl protein -tyrosine kinase inhibitor ST1571 Inhibits in vitro signal transduction mediated by c-kit and platelet —derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295 (1):139–45.
- Cichoz-Lach H, Kasztelan-Szczerbinska B, Slomka M. Gastrointestinal stromal tumors:epidemiology, clinical picture, diagnosis, prognosis and treatment. Pol Arch Med Wewn. Apr 2008; 118 (4):216–21.
- Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. Jan 2001; 438 (1):1–12.
- Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factor to guide patient selection.Cancer. 2000; 88 (1):66–74.
- Katz D, Segal A, Alberton Y, et al. Neoadjuvent imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs. 2004; 15 (6):599–602.
- Bumming P, Andersson J, Meis kindblom JM, et al. Neoadjuvent, adjuvant and palliative treatment of gastrointestinal stromal tumors with imatinib: a centre-based study of 17 patient. Br J cancer. 2003; 89 (3):460–4
- Trent J, Hunt KK. A prospective, randomized, phase II study of preoperative plus postoperative imatinib mesylate (Gleevec, formerly STI-571) in patients with primary, recurrent or metastatic resectable, kit expressing, gastrointestinal stromal tumor (GIST). Available: http//www.utm-extOla.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/index/id03-0023.
- Eisenberg B. A phase II trial neoadjuvent/adjuvant STI 571 (Gleevec NSC 716051) for primary and recurrent operable malignant GIST expressing KIT receptor tyrosine kinase (CD117). Available: http://www.rtog.org/members/protocols/s0132/s0132.pdf
- Ng EH, Pollok RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992; 69 (6):1334–41.
- Scaife CL, Hunt KK, et al. Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg.2003 Dec;186 (6):665–9.
- P.G. Casali, et al. Gastrointestinal stromal tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Annal of oncology. 2008; 19 (supplement2):1135-1138.